Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Larotaxel + cisplatin vs gemcitabine + cisplatin in first-line metastatic urothelial or bladder cancer
2007-001943-23Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of larotaxel in transitional cell carcinoma (TCC) and bladder cancer (2 arms), sponsored by Sanofi. Primary endpoint: Overall survival. Started Oct 2007; status: completed.
02
Drugs
larotaxel
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on 2007-001943-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001943-23.